At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
AZD7624 +1 moredrug
Likely dose
AZD7624 300 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD
In Brief
A Phase 1 clinical trial evaluating AZD7624 and Placebo to match for COPD and Healthy Subjects. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic obstructive pulmonary disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD, Healthy Subjects
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartSep 2013
Primary CompletionOct 2014
TodayJul 2026
First PostedMar 26, 2013
Enrollment StartSep 1, 2013
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.3 years ago
Interventions
AZD7624drug
Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
Placebo to matchdrug
Multiple doses inhaled placebo via a nebulizer